CBD and THC, both derived from the cannabis plant, are two distinct compounds with unique properties that affect the human body differently. While THC is known for its psychoactive effects, CBD is non-intoxicating and has gained recognition for its potential therapeutic benefits.
What is CBD?
Cannabidiol (CBD) is a naturally occurring compound found in the cannabis plant. It is one of over 100 cannabinoids identified in cannabis, and it has gained significant attention for its potential health benefits. CBD can be extracted from both hemp and marijuana plants, but it is most commonly derived from hemp due to its low THC content1.
CBD interacts with the body’s endocannabinoid system (ECS), which is responsible for regulating various physiological processes, such as pain, mood, appetite, and sleep. CBD binds to cannabinoid receptors (CB1 and CB2) in the ECS, modulating their activity and influencing the release of neurotransmitters2. This interaction with the ECS is believed to be the basis for CBD’s potential therapeutic effects on the body and mind.
What is THC?
Tetrahydrocannabinol (THC) is the primary psychoactive compound found in the cannabis plant. It is responsible for the “high” associated with marijuana use. Like CBD, THC interacts with the body’s endocannabinoid system, but it binds more strongly to the CB1 receptors in the brain, leading to the psychoactive effects3.
THC has been used for both recreational and medicinal purposes, with some studies suggesting potential benefits for conditions such as chronic pain, multiple sclerosis, and chemotherapy-induced nausea and vomiting4. However, the psychoactive effects of THC can also lead to adverse reactions, such as impaired memory, anxiety, and increased heart rate, especially in high doses or when consumed by sensitive individuals.
Key Differences Between CBD and THC
CBD and THC, while sharing some similarities in their molecular structure and interaction with the endocannabinoid system, have several distinct differences that set them apart. Understanding these key differences is crucial for anyone considering using cannabis products for medicinal or recreational purposes. The following table provides a concise overview of the main aspects that distinguish CBD from THC:
Aspect | CBD | THC |
---|---|---|
Psychoactive Effects | Non-psychoactive | Psychoactive |
Chemical Structure | C21H30O2 | C21H30O2 |
Interaction with ECS | Binds weakly to CB1 receptors | Binds strongly to CB1 receptors |
Legal Status (US) | Hemp-derived CBD (<0.3% THC) is federally legal | Illegal under federal law; legal for medical/recreational use in some states |
Medical Benefits | Potential benefits for anxiety, pain, epilepsy, and more | Potential benefits for pain, multiple sclerosis, nausea, and more |
Side Effects | Generally well-tolerated; may cause dry mouth, drowsiness, and interactions with medications | May cause impaired memory, dizziness, anxiety, and increased heart rate |
Psychoactive Effects
One of the most significant differences between CBD and THC lies in their psychoactive properties. THC is the primary psychoactive compound in cannabis, responsible for the “high” associated with marijuana use. When consumed, THC binds to the CB1 receptors in the brain, altering the release of neurotransmitters and leading to changes in perception, mood, and consciousness[^3^].
The effects of THC can vary from person to person but may include:
- Euphoria and relaxation
- Altered perception of time
- Heightened sensory awareness
- Increased appetite
- Impaired memory and concentration
- Dry mouth and eyes
- Increased heart rate
- Anxiety or paranoia (in high doses or sensitive individuals)
In contrast, CBD is non-psychoactive and does not produce the “high” associated with THC. While CBD does interact with the endocannabinoid system, it has a low affinity for CB1 receptors and does not cause the same psychoactive effects as THC5. In fact, CBD has been shown to counteract some of the negative psychoactive effects of THC, such as anxiety and paranoia6.
This difference in psychoactivity is a crucial factor for individuals who want to experience the potential therapeutic benefits of cannabis without the mind-altering effects. It also has significant implications for the legal status and accessibility of CBD and THC products.
Chemical Structure
CBD and THC have very similar chemical structures, both containing 21 carbon atoms, 30 hydrogen atoms, and 2 oxygen atoms (C21H30O2). However, the arrangement of these atoms differs slightly between the two compounds, which leads to their distinct effects on the human body7.
CBD and THC are both cyclic compounds, meaning they contain one or more rings of carbon atoms. They are classified as tricyclic terpenoids, sharing a similar three-dimensional structure. The main difference lies in the position of a hydroxyl group (OH) and a carbon-carbon double bond (C=C)8.
In CBD, the hydroxyl group is located on the seventh carbon atom, while the double bond is between the eighth and ninth carbon atoms. In contrast, THC has the hydroxyl group on the eighth carbon atom and the double bond between the ninth and tenth carbon atoms. This subtle difference in the location of the hydroxyl group and double bond is responsible for the different pharmacological properties of CBD and THC9.
The structural similarity between CBD and THC allows them to interact with the body’s endocannabinoid system, but the slight variation in their structures leads to different binding affinities for the CB1 and CB2 receptors, resulting in their unique effects on the mind and body.
Interaction with the Endocannabinoid System
CBD and THC both interact with the body’s endocannabinoid system (ECS), a complex network of receptors, endogenous cannabinoids (endocannabinoids), and enzymes that play a crucial role in regulating various physiological processes, such as pain, mood, appetite, and immune function[^2^].
The two main types of cannabinoid receptors in the ECS are CB1 and CB2 receptors. CB1 receptors are primarily found in the central nervous system, while CB2 receptors are more abundant in the peripheral nervous system and immune cells10.
THC binds directly to CB1 receptors, acting as a partial agonist. This means that it activates these receptors, leading to the psychoactive effects associated with marijuana use, such as euphoria, altered perception, and impaired memory[^3^]. THC also binds to CB2 receptors, but with a lower affinity compared to CB1 receptors.
In contrast, CBD has a low affinity for both CB1 and CB2 receptors and does not directly activate them like THC does. Instead, CBD modulates the activity of these receptors indirectly by influencing the availability of endocannabinoids, such as anandamide, and by affecting the activity of other receptors and neurotransmitter systems11.
For example, CBD has been shown to inhibit the enzymes that break down anandamide, leading to increased levels of this endocannabinoid in the body. Anandamide is known as the “bliss molecule” and is involved in regulating mood, pain, and appetite12. By enhancing anandamide signaling, CBD may exert some of its potential therapeutic effects.
Furthermore, CBD interacts with several other receptors and ion channels, such as serotonin receptors (5-HT1A), vanilloid receptors (TRPV1), and GPR55, which may contribute to its diverse range of effects on the body and mind13.
The different ways in which CBD and THC interact with the ECS and other receptor systems account for their distinct pharmacological properties and potential therapeutic applications.
Medical Benefits
Both CBD and THC have shown potential therapeutic benefits for a wide range of medical conditions. However, their distinct pharmacological properties and interaction with the endocannabinoid system result in different applications and efficacy for specific ailments.
CBD has gained significant attention for its potential to alleviate symptoms related to:
- Epilepsy: CBD has been shown to reduce the frequency and severity of seizures in patients with rare forms of epilepsy, such as Dravet syndrome and Lennox-Gastaut syndrome. The FDA has approved a CBD-based medication, Epidiolex, for the treatment of these conditions14.
- Anxiety and Depression: CBD has demonstrated anxiolytic (anti-anxiety) and antidepressant-like effects in animal studies and human trials, possibly due to its interaction with serotonin receptors15.
- Pain and Inflammation: CBD has been studied for its potential analgesic and anti-inflammatory properties, which may be useful in managing chronic pain conditions, such as arthritis and multiple sclerosis16.
- Neurological Disorders: CBD has shown promise in preclinical studies for its potential neuroprotective and anti-inflammatory effects, which may be beneficial in treating neurodegenerative disorders like Alzheimer’s and Parkinson’s disease17.
THC, on the other hand, has been primarily investigated for its potential benefits in:
- Chronic Pain: THC has been shown to reduce chronic pain associated with conditions like cancer, neuropathy, and fibromyalgia, often in combination with CBD18.
- Multiple Sclerosis: THC may help alleviate spasticity, pain, and bladder dysfunction in patients with multiple sclerosis. A THC and CBD combination drug, Sativex, has been approved in several countries for the treatment of MS-related spasticity19.
- Chemotherapy-Induced Nausea and Vomiting: THC has antiemetic properties and has been used to treat nausea and vomiting associated with cancer chemotherapy. Synthetic THC medications, such as Dronabinol and Nabilone, have been approved by the FDA for this purpose.
- Appetite Stimulation: THC has been shown to stimulate appetite and may be beneficial for patients with HIV/AIDS or cancer cachexia who experience significant weight loss20.
It is important to note that while both CBD and THC show promise in various medical applications, more research is needed to fully understand their efficacy, optimal dosing, and long-term safety. Additionally, the potential benefits should be weighed against the possible side effects and legal considerations when using these compounds for therapeutic purposes.
Side Effects
While both CBD and THC are generally considered safe, they can cause side effects, which vary in severity and prevalence. The side effect profile of these compounds is related to their distinct pharmacological properties and interaction with the endocannabinoid system.
CBD is well-tolerated in humans, even at high doses, and has a favorable safety profile21. Common side effects of CBD include:
- Dry mouth
- Drowsiness or fatigue
- Changes in appetite
- Diarrhea
- Interactions with certain medications (e.g., blood thinners)
These side effects are usually mild and can often be managed by adjusting the dosage or timing of CBD administration. CBD may also interact with liver enzymes responsible for metabolizing certain medications, potentially altering their effectiveness or side effects22.
THC, on the other hand, is associated with more pronounced side effects due to its psychoactive properties. These side effects can be acute or chronic and may include23:
- Impaired memory and concentration
- Altered perception of time
- Mood changes (e.g., euphoria, anxiety, or paranoia)
- Dizziness
- Dry mouth and eyes
- Increased heart rate
- Coordination problems
- Increased appetite
The severity of THC side effects can depend on factors such as dosage, route of administration, and individual tolerance. In some cases, high doses of THC or chronic use may lead to more serious side effects, such as:
- Cannabinoid Hyperemesis Syndrome (CHS): A rare condition characterized by severe nausea, vomiting, and abdominal pain in long-term, heavy cannabis users24.
- Psychiatric disorders: THC use may exacerbate or trigger latent psychiatric disorders, such as schizophrenia or psychosis, particularly in individuals with a genetic predisposition25.
- Substance use disorder: Chronic THC use can lead to the development of cannabis use disorder, characterized by a pattern of problematic use and withdrawal symptoms upon cessation26.
It is essential to note that while CBD may counteract some of the adverse effects of THC, such as anxiety and paranoia, it may not completely negate all the potential risks associated with THC use. Therefore, individuals considering using THC for medicinal or recreational purposes should be aware of the potential side effects and consult with a healthcare professional to determine if the benefits outweigh the risks in their specific case.
CBD vs. THC: Drug testing
Both CBD and THC can be detected in various drug tests, including urine, blood, saliva, and hair tests. However, the detection windows and sensitivity of these tests vary depending on factors such as the type of test, frequency of use, dosage, and individual metabolism27.
THC and its metabolites are the primary targets of most standard drug tests. These tests typically detect THC metabolites, particularly THC-COOH, which can remain in the body for several days to weeks after use, depending on the frequency and amount of consumption28.
In contrast, CBD is not usually tested for in standard drug panels. However, some CBD products may contain trace amounts of THC, which could potentially lead to a positive drug test result, especially if consumed in large quantities or over an extended period29.
It is essential for individuals who are subject to drug testing, particularly for employment or legal purposes, to be aware of the potential risks associated with consuming CBD products. To minimize the risk of a positive drug test, it is recommended to choose CBD products from reputable sources that provide third-party lab testing results and to consult with a healthcare professional before use.
CBD vs. THC: Legal Regulations
The legal status of CBD and THC varies by jurisdiction and is subject to change as laws and regulations evolve. In the United States, the legality of these compounds is determined at both the federal and state levels.
At the federal level, the 2018 Farm Bill legalized hemp and hemp-derived products, including CBD, provided that they contain less than 0.3% THC by dry weight[^11^]. This means that hemp-derived CBD products are legal under federal law, although they may still be subject to regulation by the Food and Drug Administration (FDA).
However, the legality of CBD at the state level can vary. While most states have aligned their laws with the federal government’s stance on hemp-derived CBD, some states have imposed additional restrictions or requirements on CBD products30.
THC, on the other hand, remains illegal under federal law. It is classified as a Schedule I controlled substance under the Controlled Substances Act, indicating a high potential for abuse and no accepted medical use31.
Despite this, many states have legalized marijuana for medical and/or recreational use. As of April 2023, 38 states, along with Washington D.C. and several U.S. territories, have legalized medical marijuana, and 24 states have legalized recreational cannabis use for adults.
In states where marijuana is legal, the possession and use of THC may be permitted within the confines of the state’s specific regulations, such as age restrictions, possession limits, and licensed dispensaries.
It is crucial for individuals to stay informed about the specific laws and regulations governing CBD and THC in their jurisdiction, as the legal landscape continues to evolve. Additionally, it is essential to consider the potential legal implications of using these compounds, especially in situations where drug testing may be required.
Frequently Asked Questions
Can CBD get you high?
No, CBD is non-psychoactive and does not produce the “high” associated with THC.
Is CBD legal?
Hemp-derived CBD products containing less than 0.3% THC are federally legal in the United States, but state laws can vary.
What are the potential health benefits of CBD?
CBD has been studied for its potential to alleviate anxiety, pain, inflammation, seizures, and other conditions, but more research is needed to fully understand its efficacy.
What are the side effects of THC?
THC can cause side effects such as impaired memory and concentration, dizziness, anxiety, paranoia, and increased heart rate.
Can you fail a drug test due to CBD?
While CBD itself should not cause a positive drug test result, some CBD products may contain trace amounts of THC that could lead to a positive test.
Conclusion
CBD and THC, while sharing some similarities, have distinct properties that set them apart. Understanding these differences is crucial for anyone considering using cannabis products for medicinal or recreational purposes. Always consult with a healthcare professional before using CBD or THC, and be aware of the legal regulations in your area.
References:
- Corroon, J., & Phillips, J. A. (2018). A Cross-Sectional Study of Cannabidiol Users. Cannabis and Cannabinoid Research, 3(1), 152–161. https://pubmed.ncbi.nlm.nih.gov/30014038/ ↩︎
- Pertwee, R. G. (2008). The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: Δ9-tetrahydrocannabinol, cannabidiol and Δ9-tetrahydrocannabivarin. British Journal of Pharmacology, 153(2), 199–215. https://pubmed.ncbi.nlm.nih.gov/17828291/ ↩︎
- Atakan, Z. (2012). Cannabis, a complex plant: Different compounds and different effects on individuals. Therapeutic Advances in Psychopharmacology, 2(6), 241–254. https://pmc.ncbi.nlm.nih.gov/articles/PMC3736954/ ↩︎
- National Academies of Sciences, Engineering, and Medicine. (2017). The Health Effects of Cannabis and Cannabinoids: The Current State of Evidence and Recommendations for Research. Washington, DC: The National Academies Press. https://www.ncbi.nlm.nih.gov/books/NBK423845/ ↩︎
- Niesink, R. J. M., & van Laar, M. W. (2013). Does Cannabidiol Protect Against Adverse Psychological Effects of THC? Frontiers in Psychiatry, 4. https://pubmed.ncbi.nlm.nih.gov/24137134/ ↩︎
- Zuardi, A. W., Shirakawa, I., Finkelfarb, E., & Karniol, I. G. (1982). Action of cannabidiol on the anxiety and other effects produced by δ9-THC in normal subjects. Psychopharmacology, 76(3), 245–250. https://pubmed.ncbi.nlm.nih.gov/6285406/ ↩︎
- Russo, E. B. (2011). Taming THC: Potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. British Journal of Pharmacology, 163(7), 1344–1364. https://pubmed.ncbi.nlm.nih.gov/21749363/ ↩︎
- ElSohly, M. A., & Gul, W. (2014). Constituents of Cannabis Sativa. In R. G. Pertwee (Ed.), Handbook of Cannabis (pp. 3–22). Oxford University Press. https://academic.oup.com/book/27329/chapter-abstract/197023611?redirectedFrom=fulltext ↩︎
- Hanuš, L. O., Meyer, S. M., Muñoz, E., Taglialatela-Scafati, O., & Appendino, G. (2016). Phytocannabinoids: A unified critical inventory. Natural Product Reports, 33(12), 1357–1392. https://pubmed.ncbi.nlm.nih.gov/27722705/ ↩︎
- Mackie, K. (2008). Cannabinoid receptors: Where they are and what they do. Journal of Neuroendocrinology, 20(s1), 10–14. https://onlinelibrary.wiley.com/doi/10.1111/j.1365-2826.2008.01671.x ↩︎
- Laprairie, R. B., Bagher, A. M., Kelly, M. E. M., & Denovan-Wright, E. M. (2015). Cannabidiol is a negative allosteric modulator of the cannabinoid CB1 receptor. British Journal of Pharmacology, 172(20), 4790–4805. https://pubmed.ncbi.nlm.nih.gov/26218440/ ↩︎
- Leweke, F. M., Piomelli, D., Pahlisch, F., Muhl, D., Gerth, C. W., Hoyer, C., Klosterkötter, J., Hellmich, M., & Koethe, D. (2012). Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia. Translational Psychiatry, 2(3), e94. https://www.nature.com/articles/tp201215 ↩︎
- Russo, E. B., Burnett, A., Hall, B., & Parker, K. K. (2005). Agonistic properties of cannabidiol at 5-HT1a receptors. Neurochemical Research, 30(8), 1037–1043. https://pubmed.ncbi.nlm.nih.gov/16258853/ ↩︎
- U.S. Food and Drug Administration. (2020, August 3). FDA Approves New Indication for Drug Containing an Active Ingredient Derived from Cannabis to Treat Seizures in Rare Genetic Disease. https://www.fda.gov/news-events/public-health-focus/fda-regulation-cannabis-and-cannabis-derived-products-including-cannabidiol-cbd ↩︎
- Crippa, J. A. S., Guimarães, F. S., Campos, A. C., & Zuardi, A. W. (2018). Translational Investigation of the Therapeutic Potential of Cannabidiol (CBD): Toward a New Age. Frontiers in Immunology, 9. https://www.semanticscholar.org/paper/Translational-Investigation-of-the-Therapeutic-of-a-Crippa-Guimar%C3%A3es/d2c0b77b99bc82b39d91629050b921b540dcfbdd ↩︎
- Russo, E. B. (2008). Cannabinoids in the management of difficult to treat pain. Therapeutics and Clinical Risk Management, 4(1), 245–259. https://pubmed.ncbi.nlm.nih.gov/18728714/ ↩︎
- Iuvone, T., Esposito, G., De Filippis, D., Scuderi, C., & Steardo, L. (2009). Cannabidiol: A Promising Drug for Neurodegenerative Disorders? CNS Neuroscience & Therapeutics, 15(1), 65–75. https://onlinelibrary.wiley.com/doi/10.1111/j.1755-5949.2008.00065.x ↩︎
- Lynch, M. E., & Campbell, F. (2011). Cannabinoids for treatment of chronic non-cancer pain; a systematic review of randomized trials. British Journal of Clinical Pharmacology, 72(5), 735–744. https://pubmed.ncbi.nlm.nih.gov/21426373/ ↩︎
- Zajicek, J. P., & Apostu, V. I. (2011). Role of Cannabinoids in Multiple Sclerosis. CNS Drugs, 25(3), 187–201. https://www.researchgate.net/publication/49838190_Role_of_Cannabinoids_in_Multiple_Sclerosis ↩︎
- Beal, J. E., Olson, R., Laubenstein, L., Morales, J. O., Bellman, P., Yangco, B., Lefkowitz, L., Plasse, T. F., & Shepard, K. V. (1995). Dronabinol as a treatment for anorexia associated with weight loss in patients with AIDS. Journal of Pain and Symptom Management, 10(2), 89–97. https://www.semanticscholar.org/paper/Dronabinol-as-a-treatment-for-anorexia-associated-Beal-Olson/c095489adde8776d641b491980bb057bb656db9b ↩︎
- Iffland, K., & Grotenhermen, F. (2017). An Update on Safety and Side Effects of Cannabidiol: A Review of Clinical Data and Relevant Animal Studies. Cannabis and Cannabinoid Research, 2(1), 139–154. https://pubmed.ncbi.nlm.nih.gov/28861514/ ↩︎
- Jiang, R., Yamaori, S., Takeda, S., Yamamoto, I., & Watanabe, K. (2011). Identification of cytochrome P450 enzymes responsible for metabolism of cannabidiol by human liver microsomes. Life Sciences, 89(5–6), 165–170. https://unique-therapeutics.com/wp-content/uploads/2023/01/Identification-of-cytochrome-P450-enzymes-responsible-for-metabolism-of-cannabidiol-by-human-liver-microsomes.pdf ↩︎
- Volkow, N. D., Baler, R. D., Compton, W. M., & Weiss, S. R. B. (2014). Adverse Health Effects of Marijuana Use. New England Journal of Medicine, 370(23), 2219–2227. https://www.nejm.org/doi/full/10.1056/NEJMra1402309 ↩︎
- Allen, J. H., de Moore, G. M., Heddle, R., & Twartz, J. C. (2004). Cannabinoid hyperemesis: Cyclical hyperemesis in association with chronic cannabis abuse. Gut, 53(11), 1566–1570. https://gut.bmj.com/content/53/11/1566 ↩︎
- Radhakrishnan, R., Wilkinson, S. T., & D’Souza, D. C. (2014). Gone to Pot – A Review of the Association between Cannabis and Psychosis. Frontiers in Psychiatry, 5. https://www.frontiersin.org/journals/psychiatry/articles/10.3389/fpsyt.2014.00054/full ↩︎
- Budney, A. J., Roffman, R., Stephens, R. S., & Walker, D. (2007). Marijuana Dependence and Its Treatment. Addiction Science & Clinical Practice, 4(1), 4–16. https://drugfree.org.au/images/pdf-files/library/Cannabis/MarijuanaDependenceTreatment.pdf ↩︎
- Sharma, P., Murthy, P., & Bharath, M. M. S. (2012). Chemistry, Metabolism, and Toxicology of Cannabis: Clinical Implications. Iranian Journal of Psychiatry, 7(4), 149–156. https://pubmed.ncbi.nlm.nih.gov/23408483/ ↩︎
- Huestis, M. A. (2007). Human Cannabinoid Pharmacokinetics. Chemistry & Biodiversity, 4(8), 1770–1804. https://pubmed.ncbi.nlm.nih.gov/17712819/ ↩︎
- Nahler, G., Grotenhermen, F., Zuardi, A. W., & Crippa, J. A. S. (2017). A Conversion of Oral Cannabidiol to Delta9-Tetrahydrocannabinol Seems Not to Occur in Humans. Cannabis and Cannabinoid Research, 2(1), 81–86. https://www.liebertpub.com/doi/10.1089/can.2017.0009 ↩︎
- Mead, A. (2019). Legal and Regulatory Issues Governing Cannabis and Cannabis-Derived Products in the United States. Frontiers in Plant Science, 10. https://www.frontiersin.org/journals/plant-science/articles/10.3389/fpls.2019.00697/full ↩︎
- Drug Enforcement Administration. (2020). Drug Scheduling. https://www.dea.gov/drug-information/drug-scheduling ↩︎